Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

Detalles Bibliográficos
Autores principales: Wang, Chen, McGraw, Kathy L., McLemore, Amy F., Komrokji, Rami, Basiorka, Ashley A., Al Ali, Najla, Lancet, Jeffrey E., Padron, Eric, Kosmider, Olivier, Fontenay, Michaela, Fenaux, Pierre, List, Alan F., Sallman, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883562/
https://www.ncbi.nlm.nih.gov/pubmed/34320786
http://dx.doi.org/10.3324/haematol.2021.278855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883562/
https://www.ncbi.nlm.nih.gov/pubmed/34320786
http://dx.doi.org/10.3324/haematol.2021.278855

Ejemplares similares